This figure (called the 'cost–effectiveness plane') presents the incremental effectiveness and costs of oral bisphosphonates compared with no treatment at real-world and full adherence levels.
Figure 3 presents the results of the PSA in the cost–effectiveness plane for the THR population. The majority of samples plot in the first quadrant, indicating that rivaroxaban was both more ...